background
intraven
immunoglobulin
ivig
usual
use
support
therapi
treatment
ivig
controversi
rapid
review
aim
explor
clinic
effect
safeti
ivig
treatment
children
sever
method
systemat
search
literatur
use
ivig
patient
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
includ
adult
children
assess
risk
bia
qualiti
evid
report
main
find
descript
result
total
articl
identifi
initi
literatur
search
final
six
studi
includ
one
random
control
trial
rct
four
case
seri
one
case
report
involv
patient
one
case
seri
show
surviv
patient
acut
respiratori
distress
syndrom
ard
improv
ivig
one
case
report
show
highdos
ivig
could
improv
outcom
adult
three
observ
studi
show
inconsist
result
effect
ivig
sar
patient
one
rct
show
ivig
reduc
mortal
incid
nosocomi
infect
adult
sever
sar
qualiti
evid
low
low
exist
evid
insuffici
support
efficaci
safeti
ivig
treatment
coronaviru
diseas
covid
first
report
china
decemb
infecti
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
belong
famili
coronavirus
envelop
virus
caus
ill
rang
common
cold
sever
diseas
sar
mer
epidem
massiv
influenc
public
health
peopl
daili
live
diseas
declar
pandem
march
popul
suscept
infect
research
show
children
like
infect
adult
februari
confirm
case
mainland
china
age
year
age
year
main
symptom
children
fever
cough
diseas
averag
less
sever
children
adult
howev
sever
case
report
also
children
far
specif
treatment
antivir
therapi
vaccin
current
develop
ivig
prepar
plasma
healthi
human
usual
use
support
therapi
main
compon
immunoglobulin
ig
g
dual
therapeut
effect
immunemodul
effect
immun
substitut
ivig
one
altern
treatment
children
agammaglobulinemia
effect
treatment
kawasaki
diseas
ivig
use
treat
sar
patient
sar
outbreak
convinc
evid
effect
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
accord
recent
report
patient
sever
receiv
ivig
china
publish
guidelin
indic
ivig
could
use
treat
children
sever
critic
diseas
purpos
studi
perform
comprehens
rapid
review
explor
whether
benefici
treat
children
sever
ivig
provid
support
evid
support
guidelin
urgent
situat
review
regist
carri
comprehens
search
follow
electron
databas
data
use
term
novel
coronaviru
coronaviru
sar
mer
ivig
intraven
immunoglobulin
deriv
search
cover
time
databas
incept
march
search
strategi
determin
multipl
presearch
discuss
clinician
appel
diseas
ivig
also
search
world
health
organ
clinic
trial
registri
platform
isrctn
registri
clinicaltri
googl
scholar
three
preprint
servic
includ
medrxiv
http
wwwmedrxivorg
biorxiv
http
wwwbiorxivorg
ssrn
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
primari
outcom
risk
death
sever
diseas
secondari
outcom
includ
incid
nosocomi
infect
durat
hospit
clinic
symptom
absorpt
lung
lesion
improv
abnorm
biochem
indic
advers
effect
exclud
duplic
confer
abstract
comment
letter
studi
publish
languag
english
chines
studi
could
access
full
text
elimin
duplic
endnot
softwar
manual
check
two
review
j
zhang
yang
independ
review
titl
abstract
record
retriev
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
search
select
potenti
relev
studi
accord
predefin
inclus
exclus
criteria
review
screen
full
text
made
final
select
pilot
search
conduct
full
screen
literatur
ensur
research
understood
screen
criteria
process
disagr
select
studi
resolv
consult
third
parti
n
yang
process
studi
select
document
use
prisma
flow
diagram
two
review
j
zhang
yang
independ
extract
follow
data
includ
trial
use
standard
extract
sheet
basic
inform
year
public
first
author
affili
journal
fund
conflict
interest
studi
detail
type
studi
sampl
size
research
purpos
research
popul
characterist
intervent
outcom
data
pretest
conduct
formal
extract
ensur
research
agre
extract
criteria
process
disagr
solv
discuss
third
research
n
yang
two
review
j
zhang
assess
qualiti
includ
studi
independ
use
cochran
bia
risk
assess
tool
risk
bia
assess
random
control
trial
clinic
control
trial
criteria
recommend
nation
institut
health
clinic
optim
nice
case
seri
assess
risk
bia
joanna
brigg
institut
jbi
case
report
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
qualiti
apprais
tool
case
report
newcastleottawa
qualiti
assess
scale
no
qualiti
cohort
studi
casecontrol
studi
agenc
healthcar
research
qualiti
ahrq
tool
crosssect
studi
dichotom
outcom
calcul
risk
ratio
rr
correspond
confid
interv
ci
p
valu
continu
outcom
calcul
mean
differ
md
correspond
ci
mean
standard
deviat
sd
report
suffici
data
avail
consid
examin
robust
metaanalys
sensit
analysiswhen
effect
size
could
pool
report
studi
effect
narr
qualiti
bodi
evid
grade
use
grade
method
evid
random
trial
could
downgrad
follow
five
factor
risk
bia
inconsist
result
indirect
evid
imprecis
result
public
bia
qualiti
evid
outcom
grade
high
medium
low
low
result
grade
present
grade
evid
profil
identifi
articl
initi
literatur
search
figur
remov
duplic
screen
titl
abstract
record
thirtyon
articl
retriev
fulltext
review
final
one
rct
four
case
seri
one
case
report
involv
total
patient
includ
rapid
review
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
studi
publish
studi
china
tabl
tabl
found
one
case
seri
ivig
adult
ard
one
case
report
adult
one
random
control
trial
adult
sever
sar
includ
adult
acut
lung
injuri
ali
adult
ard
one
case
seri
involv
children
sar
two
case
seri
also
involv
adult
sar
outcom
studi
durat
fever
total
peripher
blood
wbc
time
lung
lesion
subsid
obvious
advers
effect
wbc
count
platelet
count
serum
globulin
incid
nosocomi
infect
risk
death
surviv
probabl
progress
diseas
cascad
studi
ivig
use
combin
drug
treatment
antibiot
glucocorticoid
antivir
oxygen
therapi
ivig
dose
durat
use
differ
across
studi
found
high
risk
bia
random
sequenc
alloc
conceal
blind
includ
rct
case
seri
moder
risk
score
one
case
report
meet
item
jbi
qualiti
apprais
tool
tabl
qualiti
evid
outcom
assess
includ
rct
grade
low
tabl
primarili
due
seriou
risk
bia
imprecis
includ
four
case
seri
judg
report
grade
evid
profil
would
meaning
overal
qualiti
evid
low
outcom
thu
provid
reliabl
indic
like
effect
across
outcom
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
case
seri
adult
report
patient
use
antibiot
antivir
treatment
half
patient
given
glucocorticoid
therapi
ivig
surviv
probabl
patient
ard
could
improv
antivir
glucocorticoid
immunoglobulin
treatment
risk
death
associ
use
ivig
patient
ard
case
report
three
adult
report
high
dose
ivig
gd
day
administ
appropri
point
could
success
block
progress
diseas
cascad
result
clinic
symptom
laboratori
inspect
indic
chest
ct
scan
final
improv
outcom
covid
random
control
trial
adult
sever
sar
found
signific
differ
risk
death
vs
incid
nosocomi
infect
vs
adult
treat
either
ivig
convent
treatment
signific
differ
incid
nosocomi
infect
ali
vs
ard
vs
patient
one
case
seri
report
patient
sar
receiv
steroid
sever
hemocytopenia
increas
wbc
count
platelet
count
undergo
ivig
anoth
case
seri
report
children
persist
fever
given
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
ivig
significantli
improv
total
peripher
blood
wbc
undergo
ivig
includ
rct
show
serum
globulin
increas
slightli
ivig
group
decreas
convent
treatment
group
differ
signific
one
case
seri
includ
ten
children
persist
fever
given
ivig
bodi
temperatur
rang
baselin
durat
fever
day
ivig
one
case
seri
report
chest
radiograph
children
given
ivig
show
patchi
focal
asymmetr
infiltr
shadow
rapid
time
lung
lesion
subsid
obvious
randomli
select
ageand
sexmatch
control
group
children
without
ivig
one
case
seri
report
advers
effect
associ
ivig
ivig
use
patient
high
fever
obviou
poison
symptom
earli
stage
diseas
treat
glucocorticoid
whose
white
blood
cell
count
l
found
limit
evid
use
ivig
treat
children
adult
sever
sinc
sar
belong
famili
virus
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
use
ivig
treatment
sar
indirect
evid
even
though
qualiti
includ
studi
gener
low
result
also
inconsist
benefit
found
identifi
random
control
trial
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
infect
compar
placebo
intervent
ivig
prepar
pool
plasma
obtain
sever
thousand
healthi
blood
donor
unlik
convalesc
plasma
patient
ivig
contain
neutral
antibodi
review
show
evid
ivig
effect
antimerscov
ivig
would
caus
kidney
failur
thrombosi
patient
mer
ivig
could
increas
risk
vaccin
delay
studi
nation
advisori
committe
immun
american
advisori
committe
immun
show
delay
five
month
varicella
vaccin
patient
receiv
ivig
varicella
immun
globulin
vzig
ivig
may
increas
risk
infect
transmit
transfus
advers
effect
thrombosi
asept
mening
hemolysi
renal
failur
mainli
associ
use
highdos
ivig
condit
dose
durat
ivig
inconsist
studi
efficaci
associ
advers
effect
remain
unclear
first
sever
case
children
china
took
ivig
dose
mgkg
durat
five
day
recommend
dosag
ivig
children
sever
also
inconsist
differ
guidelin
includ
day
day
day
day
therefor
particularli
import
urgent
studi
benefit
disadvantag
ivig
treatment
children
promis
trial
address
efficaci
safeti
ivig
therapi
patient
sever
critic
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
first
systemat
review
ivig
treatment
children
sever
limit
systemat
review
first
use
glucocorticoid
combin
varieti
broadspectrum
antibiot
ivig
may
lead
chang
microecolog
bodi
affect
immun
regul
function
thu
also
affect
effect
ivig
second
total
sampl
size
studi
insuffici
make
strong
conclus
qualiti
methodolog
gener
low
affect
certainti
result
final
may
miss
studi
includ
studi
publish
chines
english
direct
evid
ivig
children
current
evid
insuffici
assess
effect
safeti
ivig
children
sever
therefor
suggest
use
ivig
treatment
children
clinic
studi
address
topic
need
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
thank
jann
estil
institut
global
health
univers
geneva
provid
guidanc
comment
review
thank
author
wonder
collabor
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
explod
tree
ti
ab
kw
ti
ab
kw
novel
coronaviru
ti
ab
kw
coronaviru
ti
ab
kw
novel
cov
ti
ab
kw
ti
ab
kw
ti
ab
kw
coronaviru
ti
ab
kw
coronaviru
diseas
ti
ab
kw
covid
ti
ab
kw
wuhancov
ti
ab
kw
wuhan
coronaviru
ti
ab
kw
wuhan
seafood
market
pneumonia
viru
ti
ab
kw
middl
east
respiratori
syndrom
ti
ab
kw
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
topic
novel
cov
topic
topic
topic
wuhancov
topic
wuhan
coronaviru
topic
wuhan
seafood
market
pneumonia
viru
topic
middl
east
respiratori
syndrom
topic
mer
topic
merscov
topic
sever
acut
respiratori
syndrom
topic
sar
topic
sarscov
topic
sarsrel
topic
sarsassoci
topic
intraven
immunoglobulin
topic
intraven
ig
topic
immun
globulin
topic
ivig
topic
iv
immunoglobulin
topic
intraven
antibodi
topic
gamma
globulin
topic
gammaglobulin
topic
flebogamma
dif
topic
gamun
topic
globulinn
topic
globulin
n
topic
intraglobin
topic
gammagard
topic
gamimun
topic
gamimmun
topic
privigen
topic
sandoglobulin
topic
venoglobulin
topic
iveegam
topic
endobulin
topic
gammonativ
cbm
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
drug
interferon
hormon
etc
intervent
valu
squar
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
